New Developments in Chronic Myeloid Leukemia: Implications for Therapy.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by excessive myeloid cell production.
• The Philadelphia chromosome (Ph) and BCR-ABL1 fusion protein are hallmarks of CML, driving malignant transformation.
• Tyrosine kinase inhibitors (TKIs) like imatinib have transformed CML treatment, with dasatinib and nilotinib offering improved efficacy.

Purpose of the Study:

• To review the challenges in CML therapy, focusing on TKI resistance and efficacy.
• To highlight the need for deeper understanding of resistance mechanisms and stem cell behavior.
• To emphasize the importance of this knowledge for developing novel curative strategies.

Main Methods:

• Review of existing literature on CML pathogenesis and treatment.
• Analysis of mechanisms underlying BCR-ABL1 tyrosine kinase inhibitor (TKI) resistance.
• Examination of TKI efficacy in different CML phases and against CML stem cells.

Main Results:

• TKI resistance in CML can arise from BCR-ABL1 overexpression, altered drug transport, alternative signaling, or kinase domain mutations.
• BCR-ABL1 TKIs show limited effectiveness in blast crisis (BC) CML.
• Quiescent CML stem cells are insensitive to conventional chemotherapeutics and BCR-ABL1 TKIs.

Conclusions:

• Understanding TKI resistance mechanisms is crucial for overcoming treatment limitations in CML.
• Addressing the insensitivity of CML stem cells to current therapies is essential for achieving cures.
• Further research into genomic instability and stem cell quiescence is vital for developing curative CML strategies.